RxDoctor Payments Data

Katayun Adhami, MD

MOHS-Micrographic Surgery · Boston, MANPI 1679867766

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $303, more than ten times the $24 reported in 2022. That places this record below the midpoint for mohs-micrographic surgery clinicians in MA, where the typical reported total is $746.

$560in general payments, 2019–2025

Across 22 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$128
  • AbbVie$87
  • Revance Therapeutics, Inc.$64
  • Regeneron Healthcare Solutions, Inc.$58
  • Novartis$32
  • Incyte Corporation$28
  • plus $163 from 8 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$560 in reported general payments places this provider in the 40th percentile of 38 mohs-micrographic surgery providers in Massachusetts.

See all mohs-micrographic surgery providers in Massachusetts

Medicare billing

Part B allowed, 2024
$206,886
Medicare patients
145
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Monohydrate33$361
Mupirocin23$195
Doxycycline Hyclate23$103
Amoxicillin12$6

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →